GlaxoSmithKline (GSK) and XenoPort, Inc. (XNPT) Report Positive Results from Clinical Trial
Friday, GlaxoSmithKline (NYSE:GSK) and XenoPort, Inc. (NASDAQ:XNPT) announced top-line results from a Phase II-b clinical trial. The study evaluates the safety and efficacy of GSK1838262/XP13512 (gabapentin enacarbil) for neuropathic pain, associated with post-herpetic neuralgia (PHN) in adults. The company reported that subjects were randomized to receive placebo, 1200, 2400 or 3600 mg/day of GSK1838262 dosed twice a day; all patients treated with GSK1838262 demonstrated statistically significant improvements over the control group. The primary endpoint was the change from baseline to the end of maintenance treatment in the 24-hour average pain intensity score. The 14-week, double-blind study enrolled 376 subjects with…